Kratom Lab Testing in 2026: How Alkaloid Quantification Works and Why Results Vary So Widely

The kratom industry operates in a regulatory gray zone that makes dietary supplement compliance look simple by comparison. Brands are moving tens of millions of dollars’ worth of product annually, FDA has not approved kratom for any use, six states have banned it outright, and most of the country has no potency or purity standard on the books. Into that vacuum, third-party lab testing has become one of the only quality control mechanisms that actually exists — and yet, not all kratom testing is created equal.

What shows up on a COA depends almost entirely on the methods a lab used. The gap between a colorimetric total-alkaloid screen and a properly validated LC-MS/MS quantification of individual alkaloids is enormous. For brands, that distinction isn’t academic. It can mean the difference between a defensible product and one that generates an FDA warning letter, a state enforcement action, or worse — a consumer adverse event that lands on a regulator’s desk.

The Alkaloid Profile: What You’re Actually Measuring

Kratom (Mitragyna speciosa) contains more than 40 identified alkaloids, but two dominate from a regulatory and safety standpoint: mitragynine and 7-hydroxymitragynine (commonly abbreviated 7-OH-mitragynine).

Mitragynine is the primary alkaloid by weight. In commercial kratom leaf and powder sourced from Southeast Asia — Indonesia supplies the vast majority of the US market — mitragynine typically represents 1% to 2% of dry weight. We’ve seen samples run as high as 2.7% and as low as 0.5% depending on the plant’s origin, harvest timing, vein color, and drying method. That’s a roughly 5-fold variation in the primary active compound, with no federal standard requiring any label to reflect it.

7-OH-mitragynine is present in far smaller concentrations, generally 0.01% to 0.04% by weight in raw leaf. But it’s the compound that has attracted the most regulatory scrutiny because of its significantly higher affinity for mu-opioid receptors. Research published in Journal of Medicinal Chemistry has found it to be substantially more potent than mitragynine at those receptors — which is precisely why the FDA has been watching it closely, and why accurate quantification of 7-OH-mitragynine is not optional for any brand making safety claims.

There are also corynantheidine, speciociliatine, and paynantheine in the alkaloid mix. These contribute to the plant’s overall pharmacology in ways that researchers are still characterizing. For testing purposes, brands selling standardized extracts should understand that “standardized to mitragynine” tells consumers nothing about the rest of the alkaloid profile — including 7-OH-mitragynine.

How Labs Quantify Mitragynine: Method Matters More Than the Number

This is where the COAs in circulation diverge significantly in quality.

Colorimetric and total alkaloid assays are fast and inexpensive. They work by reacting the sample with a reagent that produces a measurable color change proportional to alkaloid content. The fundamental problem is specificity: these assays don’t distinguish between mitragynine, 7-OH-mitragynine, or any of the plant’s other alkaloids. A COA reporting “total alkaloids: 1.4%” based on a colorimetric method gives you essentially no information about actual mitragynine concentration, let alone 7-OH-mitragynine. We see these COAs regularly from products sourced through multi-tier supply chains.

HPLC with UV detection (HPLC-UV) is a meaningful step up. Chromatographic separation before measurement means you can get individual compound data rather than a pooled total. For routine quality control — confirming a powder is in the expected mitragynine range, checking for gross concentration anomalies — HPLC-UV with certified reference standards is adequate. Most reputable domestic kratom brands should be operating at this level at minimum.

LC-MS/MS (liquid chromatography tandem mass spectrometry) is the gold standard. It provides the specificity and sensitivity required to accurately quantify 7-OH-mitragynine, confirm compound identity through mass spectral matching, and detect trace adulterants or undeclared substances at the sub-microgram-per-gram level. For any brand making quantitative label claims about alkaloid potency, or any product facing regulatory scrutiny, LC-MS/MS is the only method that produces fully defensible data.

The practical problem: a significant portion of COAs circulating in the kratom market are produced using HPLC-UV at best, colorimetric methods at worst. And the COA format rarely discloses which method was used unless the buyer knows to ask. A confident-looking number reported to three decimal places from a non-accredited offshore lab should prompt questions, not confidence.

Contaminant Testing: Heavy Metals, Microbiology, and Adulterants

Alkaloid quantification is only one dimension of a complete kratom test package. Contaminant testing matters at least as much — and in some cases more — for consumer safety.

Heavy metals are a documented concern. As a raw botanical grown predominantly in tropical soils in Indonesia, Malaysia, and Thailand, kratom can accumulate lead, arsenic, cadmium, and mercury depending on agricultural conditions and processing practices. Published analyses of commercial kratom products have found that a meaningful percentage of samples exceed California Prop 65 maximum allowable dose levels for lead. That’s particularly significant for California brands and for brands distributing nationally who want to keep liability exposure low. ICP-MS is the appropriate method — it can quantify all four key elemental impurities in a single analytical run at part-per-billion sensitivity, and results can be evaluated against both Prop 65 limits and the USP <2232> framework for botanical dietary supplements.

Microbiology is frequently underestimated. Kratom powder is a raw botanical material that has been harvested, dried, and processed — often without the controlled conditions of a pharmaceutical manufacturing environment. It can harbor Salmonella, E. coli, Staphylococcus aureus, and other pathogens. The FDA documented a multi-state Salmonella outbreak linked to kratom consumption, resulting in recalls of multiple products and heightened import screening. Total aerobic count, total yeast and mold, and pathogen-specific testing (particularly Salmonella absence in 25g) per USP <2021> are all required under FDA’s dietary supplement GMP regulations at 21 CFR Part 111 — and they’re what FDA will ask to see in a for-cause inspection.

Adulterant screening is the concern that gets the least public attention but carries the most serious regulatory consequence. There are documented cases of kratom products adulterated with controlled substances including tramadol, O-desmethyltramadol, and hydrocodone — all undeclared on labeling. FDA has flagged synthetic opioid contamination in kratom samples during import screening. For brands sourcing from suppliers they haven’t fully qualified, or for those who want to verify incoming material, a targeted adulterant panel by LC-MS/MS is a necessary part of supplier qualification.

The State Regulatory Patchwork and What It Actually Requires

The federal picture is stable in one sense: kratom remains unscheduled at the federal level. The DEA’s 2016 attempt to emergency-schedule mitragynine and 7-OH-mitragynine was withdrawn following significant public comment, and federal scheduling has not advanced since. But that stability hasn’t stopped state legislatures from acting on their own.

Six states have enacted outright bans: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. Brands should not ship products to these states — the legal exposure is clear and straightforward.

The more complex picture involves states that have passed versions of the Kratom Consumer Protection Act (KCPA). Georgia, Nevada, and Utah were among the first adopters; Arizona, Colorado, and Oregon have followed with their own versions. The KCPA framework generally requires that kratom products carry accurate labeling, contain no adulterated compounds, and — in several state versions — meet third-party testing requirements with documentation of alkaloid content and contaminant results.

Utah’s regulatory framework is among the most specific. It requires GMP compliance and documented COAs. The American Kratom Association (AKA) has developed a private GMP standards program that mirrors FDA’s 21 CFR Part 111 framework, and several established brands have sought AKA GMP endorsement as a differentiation signal to consumers and retail buyers.

The practical implication: brands selling in KCPA states need a COA that covers alkaloid potency and key contaminants. Brands selling nationally — or on e-commerce platforms — need that baseline plus documentation demonstrating no adulteration and pathogen absence. Because even where no specific state requirement exists, an adverse event traced to a contaminated product will involve FDA, and the COA is the first document they request.

What a Defensible Kratom Testing Package Looks Like

A complete kratom test package, in our view, covers four areas:

1. Alkaloid quantification by HPLC-UV or LC-MS/MS: mitragynine and 7-OH-mitragynine individually reported, with units expressed as percentage of dry weight and as milligrams per labeled serving. The method used should be stated explicitly on the COA.

2. Elemental analysis by ICP-MS: lead, arsenic, cadmium, and mercury, reported against California Prop 65 maximum allowable dose levels and USP <2232> limits for botanical-derived supplements.

3. Microbial testing per USP <2021>: total aerobic count, total combined yeast and mold count, E. coli (absence), and Salmonella (absence in 25g). Some brands also include S. aureus as a conditional test.

4. Adulterant screening: at minimum, a targeted panel for synthetic opioids and common kratom adulterants by LC-MS/MS.

The laboratory performing this testing should be ISO 17025 accredited, with the scope of accreditation covering the specific matrices and methods used. ISO 17025 accreditation isn’t a guarantee of method quality for every possible analyte, but it does mean the lab’s general technical competence and quality system have been independently assessed — which is a meaningful floor when the COA is the document standing between your product and regulatory scrutiny.

The kratom regulatory environment is going to continue evolving. More state KCPA legislation is likely. FDA’s ongoing regulatory review of kratom as a new dietary ingredient or drug could eventually produce federal action. Brands that invest in rigorous, method-transparent testing now aren’t just managing present-day compliance risk. They’re building the documentation record that will matter most when the regulatory picture finally crystallizes — and in this industry, that documentation may be the most defensible asset they have.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA Regulatory Strategy for Botanical and Supplement Products — Aurora TIC helps brands prepare for FDA scrutiny, build audit-ready documentation, and navigate dietary supplement gray zones.
• Raw Botanical Ingredient Testing and Supplier Qualification — Ayah Labs provides identity testing, contaminant screening, and COA verification for raw plant materials entering your supply chain.